Quipt Home Medical Corp. Completes Acquisition Arrangement: Detailed Investor Update
Quipt Home Medical Corp. Completes Acquisition Arrangement with Kingswood and Forager Affiliates
Key Highlights
- Acquisition Completed: Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT), a leading U.S. provider of home medical equipment focused on end-to-end respiratory care, has successfully completed its previously announced acquisition plan.
- Buyer Consortium: The acquisition was led by 1567208 B.C. Ltd. (“Purchaser”) with funding from Kingswood Capital Management, L.P. and Forager Capital Management, LLC, among others.
- Purchase Price: All outstanding common shares were acquired for US\$3.65 per share in cash.
- Privatisation: Following the transaction, Quipt will become a privately held entity and will cease to be traded on public exchanges.
Details Investors Need to Know
- Shareholder Implications: Shareholders received US\$3.65 in cash per share. This price may be viewed as a premium or discount depending on prior trading levels and is a key price-sensitive detail.
- Delisting: Quipt shares will be delisted from both NASDAQ and TSX at close of business on March 17, 2026. The company will apply to cease being a reporting issuer in both Canada and the U.S., ending its public reporting obligations.
- Option and RSU Treatment:
- All outstanding Quipt Options (vested or unvested) were deemed unconditionally vested, surrendered, and cancelled. Holders received a cash payment equal to the number of shares underlying the option, multiplied by the difference between \$3.65 and their exercise price. If the exercise price was greater or equal to \$3.65, the option was cancelled with no payment.
- All outstanding Restricted Share Units (RSUs) were cancelled and holders received a cash payment equal to \$3.65 (net of applicable withholdings).
- Management Commentary:
Greg Crawford, CEO, emphasized this as a transformative transaction. He thanked shareholders for their trust and support, noting that transitioning to a privately held entity strategically positions Quipt for sustained long-term success.
Representatives from Kingswood and Forager highlighted Quipt’s strong foundation, patient-first culture, and commitment to clinical excellence. Their focus will be on supporting the team, investing in the platform, and driving long-term growth.
- Advisors:
- DLA Piper acted as legal counsel for Quipt in Canada and the U.S.
- McDermott Will & Schulte LLP (U.S.) and Fasken Martineau DuMoulin LLP (Canada) advised Kingswood, Forager, and the Purchaser.
- Truist Securities served as financial advisor; Evans & Evans, Inc. served as independent financial advisor to Quipt’s Strategic Transactions Committee. UBS Investment Bank advised Kingswood exclusively.
- Carson Proxy Advisors acted as strategic shareholder advisor and proxy solicitation agent.
- Business Strategy: Quipt provides in-home monitoring and disease management services, including end-to-end respiratory solutions. It aims to expand its offerings to manage chronic diseases such as heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.
- Forward-Looking Statements: The company cautions that forward-looking statements regarding delisting, reporting changes, and expected benefits of the arrangement are subject to risks and uncertainties, including operational, regulatory, competitive, and economic factors. These could materially affect actual outcomes.
- Further Information: Shareholders seeking more details are directed to the management information circular and proxy statement dated January 23, 2026, available on SEDAR+ and EDGAR.
Potential Share Price Impact
The completion of the acquisition at a fixed cash price per share, delisting from public markets, and the end of public reporting obligations are all highly price-sensitive events. Investors should note that their shares will be converted to cash at the specified rate and will no longer be publicly traded. The final share price may represent a premium or discount relative to previous market values, and the delisting marks the end of Quipt’s status as a public company, which is a significant development for shareholders and could influence portfolio decisions.
Contact Information
Disclaimer
This article is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available documents and company disclosures as of March 16, 2026. Investors are urged to consult official company filings and their financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. The company undertakes no obligation to update any forward-looking statements except as required by law.
View Quipt Home Medical Corp. Historical chart here
